265 related articles for article (PubMed ID: 23348048)
1. Targeting IGF-IR with ganitumab inhibits tumorigenesis and increases durability of response to androgen-deprivation therapy in VCaP prostate cancer xenografts.
Fahrenholtz CD; Beltran PJ; Burnstein KL
Mol Cancer Ther; 2013 Apr; 12(4):394-404. PubMed ID: 23348048
[TBL] [Abstract][Full Text] [Related]
2. A novel calcium-dependent mechanism of acquired resistance to IGF-1 receptor inhibition in prostate cancer cells.
Fahrenholtz CD; Greene AM; Beltran PJ; Burnstein KL
Oncotarget; 2014 Oct; 5(19):9007-21. PubMed ID: 25344862
[TBL] [Abstract][Full Text] [Related]
3. Ganitumab (AMG 479) inhibits IGF-II-dependent ovarian cancer growth and potentiates platinum-based chemotherapy.
Beltran PJ; Calzone FJ; Mitchell P; Chung YA; Cajulis E; Moody G; Belmontes B; Li CM; Vonderfecht S; Velculescu VE; Yang G; Qi J; Slamon DJ; Konecny GE
Clin Cancer Res; 2014 Jun; 20(11):2947-58. PubMed ID: 24727326
[TBL] [Abstract][Full Text] [Related]
4. Effect of a low-fat diet combined with IGF-1 receptor blockade on 22Rv1 prostate cancer xenografts.
Konijeti R; Koyama S; Gray A; Barnard RJ; Said JW; Castor B; Elashoff D; Wan J; Beltran PJ; Calzone FJ; Cohen P; Galet C; Aronson WJ
Mol Cancer Ther; 2012 Jul; 11(7):1539-46. PubMed ID: 22562985
[TBL] [Abstract][Full Text] [Related]
5. In vivo effects of the human type I insulin-like growth factor receptor antibody A12 on androgen-dependent and androgen-independent xenograft human prostate tumors.
Wu JD; Odman A; Higgins LM; Haugk K; Vessella R; Ludwig DL; Plymate SR
Clin Cancer Res; 2005 Apr; 11(8):3065-74. PubMed ID: 15837762
[TBL] [Abstract][Full Text] [Related]
6. Effects of calorie restriction and IGF-1 receptor blockade on the progression of 22Rv1 prostate cancer xenografts.
Galet C; Gray A; Said JW; Castor B; Wan J; Beltran PJ; Calzone FJ; Elashoff D; Cohen P; Aronson WJ
Int J Mol Sci; 2013 Jul; 14(7):13782-95. PubMed ID: 23823800
[TBL] [Abstract][Full Text] [Related]
7. Preclinical efficacy of growth hormone-releasing hormone antagonists for androgen-dependent and castration-resistant human prostate cancer.
Fahrenholtz CD; Rick FG; Garcia MI; Zarandi M; Cai RZ; Block NL; Schally AV; Burnstein KL
Proc Natl Acad Sci U S A; 2014 Jan; 111(3):1084-9. PubMed ID: 24395797
[TBL] [Abstract][Full Text] [Related]
8. Insulin-like growth factor receptor-1 (IGF-IR) as a target for prostate cancer therapy.
Wu J; Yu E
Cancer Metastasis Rev; 2014 Sep; 33(2-3):607-17. PubMed ID: 24414227
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of ganitumab (AMG 479), alone and in combination with rapamycin, in Ewing's and osteogenic sarcoma models.
Beltran PJ; Chung YA; Moody G; Mitchell P; Cajulis E; Vonderfecht S; Kendall R; Radinsky R; Calzone FJ
J Pharmacol Exp Ther; 2011 Jun; 337(3):644-54. PubMed ID: 21385891
[TBL] [Abstract][Full Text] [Related]
10. Epitope-specific mechanisms of IGF1R inhibition by ganitumab.
Calzone FJ; Cajulis E; Chung YA; Tsai MM; Mitchell P; Lu J; Chen C; Sun J; Radinsky R; Kendall R; Beltran PJ
PLoS One; 2013; 8(2):e55135. PubMed ID: 23383308
[TBL] [Abstract][Full Text] [Related]
11. Antitumor Activity of the IGF-1/IGF-2-Neutralizing Antibody Xentuzumab (BI 836845) in Combination with Enzalutamide in Prostate Cancer Models.
Weyer-Czernilofsky U; Hofmann MH; Friedbichler K; Baumgartinger R; Adam PJ; Solca F; Kraut N; Nguyen HM; Corey E; Liu G; Sprenger CC; Plymate SR; Bogenrieder T
Mol Cancer Ther; 2020 Apr; 19(4):1059-1069. PubMed ID: 32054790
[TBL] [Abstract][Full Text] [Related]
12. AMG 479, a fully human anti-insulin-like growth factor receptor type I monoclonal antibody, inhibits the growth and survival of pancreatic carcinoma cells.
Beltran PJ; Mitchell P; Chung YA; Cajulis E; Lu J; Belmontes B; Ho J; Tsai MM; Zhu M; Vonderfecht S; Baserga R; Kendall R; Radinsky R; Calzone FJ
Mol Cancer Ther; 2009 May; 8(5):1095-105. PubMed ID: 19366899
[TBL] [Abstract][Full Text] [Related]
13. An antibody targeting the type I insulin-like growth factor receptor enhances the castration-induced response in androgen-dependent prostate cancer.
Plymate SR; Haugk K; Coleman I; Woodke L; Vessella R; Nelson P; Montgomery RB; Ludwig DL; Wu JD
Clin Cancer Res; 2007 Nov; 13(21):6429-39. PubMed ID: 17975155
[TBL] [Abstract][Full Text] [Related]
14. Antisense oligonucleotide targeting of insulin-like growth factor-1 receptor (IGF-1R) in prostate cancer.
Furukawa J; Wraight CJ; Freier SM; Peralta E; Atley LM; Monia BP; Gleave ME; Cox ME
Prostate; 2010 Feb; 70(2):206-18. PubMed ID: 19790231
[TBL] [Abstract][Full Text] [Related]
15. Growth-inhibitory effects of human anti-insulin-like growth factor-I receptor antibody (A12) in an orthotopic nude mouse model of anaplastic thyroid carcinoma.
Wang Z; Chakravarty G; Kim S; Yazici YD; Younes MN; Jasser SA; Santillan AA; Bucana CD; El-Naggar AK; Myers JN
Clin Cancer Res; 2006 Aug; 12(15):4755-65. PubMed ID: 16899627
[TBL] [Abstract][Full Text] [Related]
16. Combination of carmustine and selenite effectively inhibits tumor growth by targeting androgen receptor, androgen receptor-variants, and Akt in preclinical models: New hope for patients with castration resistant prostate cancer.
Thamilselvan V; Menon M; Thamilselvan S
Int J Cancer; 2016 Oct; 139(7):1632-47. PubMed ID: 27198552
[TBL] [Abstract][Full Text] [Related]
17. Marked response to cabazitaxel in prostate cancer xenografts expressing androgen receptor variant 7 and reversion of acquired resistance by anti-androgens.
Ylitalo EB; Thysell E; Thellenberg-Karlsson C; Lundholm M; Widmark A; Bergh A; Josefsson A; Brattsand M; Wikström P
Prostate; 2020 Feb; 80(2):214-224. PubMed ID: 31799745
[TBL] [Abstract][Full Text] [Related]
18. Steroidogenic enzyme AKR1C3 is a novel androgen receptor-selective coactivator that promotes prostate cancer growth.
Yepuru M; Wu Z; Kulkarni A; Yin F; Barrett CM; Kim J; Steiner MS; Miller DD; Dalton JT; Narayanan R
Clin Cancer Res; 2013 Oct; 19(20):5613-25. PubMed ID: 23995860
[TBL] [Abstract][Full Text] [Related]
19. Castration induces up-regulation of intratumoral androgen biosynthesis and androgen receptor expression in an orthotopic VCaP human prostate cancer xenograft model.
Knuuttila M; Yatkin E; Kallio J; Savolainen S; Laajala TD; Aittokallio T; Oksala R; Häkkinen M; Keski-Rahkonen P; Auriola S; Poutanen M; Mäkelä S
Am J Pathol; 2014 Aug; 184(8):2163-73. PubMed ID: 24949550
[TBL] [Abstract][Full Text] [Related]
20. Androgens modify therapeutic response to cabazitaxel in models of advanced prostate cancer.
Begemann D; Wang Y; Yang W; Kyprianou N
Prostate; 2020 Sep; 80(12):926-937. PubMed ID: 32542812
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
